# Proxalutamide (GT0918) Treatment for Outpatients With Mild or Moderate COVID-19 Illness

> **NCT04870606** · PHASE3 · COMPLETED · sponsor: **Suzhou Kintor Pharmaceutical Inc,** · enrollment: 733 (actual)

## Conditions studied

- Efficacy and Safety

## Interventions

- **DRUG:** Proxalutamide (GT0918)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04870606
- **Lead sponsor:** Suzhou Kintor Pharmaceutical Inc,
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-05
- **Primary completion:** 2022-01-24
- **Final completion:** 2022-04-06
- **Target enrollment:** 733 (ACTUAL)
- **Last updated:** 2024-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04870606

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04870606, "Proxalutamide (GT0918) Treatment for Outpatients With Mild or Moderate COVID-19 Illness". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04870606. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*